MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2254-2263

  Humphries, Brock ^a   Wang, Zhishan ^a   L Oom, Aaron ^a   Fisher, Theresa ^a   Tan, Dongfeng ^b   Cui, Yuehua ^a   Jiang, Yiguo ^c   Yang, Chengfeng ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 200B; PROTEIN KINASE C ALPHA; RAC1 PROTEIN; SHORT HAIRPIN RNA; MICRORNA; MIRN200 MICRORNA, HUMAN; RAC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE SILENCING; LUNG METASTASIS; MESENCHYME CELL; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, NUDE; MICRORNAS; PROTEIN KINASE C-ALPHA; RAC1 GTP-BINDING PROTEIN; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921891146     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu133     Document Type: Article

References (50)

1. Criscitiello, C. et al. (2012) Understanding the biology of triple-negative breast cancer. Ann. Oncol., 23 (suppl. 6), vi13-vi18.
2. Foulkes, W.D. et al. (2010) Triple-negative breast cancer. N. Engl. J. Med., 363, 1938-1948.
3. Bayraktar, S. et al. (2013) Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res. Treat., 138, 21-35.
4. Dent, R. et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res., 13 (15 Pt 1), 4429-4434.
5. Carey, L.A. et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res., 13, 2329-2334.
6. André, F. et al. (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann. Oncol., 23 (suppl. 6), vi46-vi51.
7. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
8. Sayed, D. et al. (2011) MicroRNAs in development and disease. Physiol. Rev., 91, 827-887.
9. Di Leva, G. et al. (2014) MicroRNAs in cancer. Annu. Rev. Pathol. Mech. Dis., 9, 287-314.
10. Wang, L. et al. (2012) MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene, 31, 2499-2511.
11. Adams, B.D. et al. (2008) Involvement of microRNAs in breast cancer. Semin. Reprod. Med., 26, 522-536.
12. Yu, Z. et al. (2010) microRNA, cell cycle, and human breast cancer. Am. J. Pathol., 176, 1058-1064.
13. Altuvia, Y. et al. (2005) Clustering and conservation patterns of human microRNAs. Nucleic Acids Res., 33, 2697-2706.
14. Michael, M.Z. et al. (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res., 1, 882-891.
15. Bracken, C.P. et al. (2008) A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res., 68, 7846-7854.
16. Gregory, P.A. et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol., 10, 593-601.
17. Korpal, M. et al. (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem., 283, 14910-14914.
18. Park, S.M. et al. (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev., 22, 894-907.
19. Burk, U. et al. (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep., 9, 582-589.
20. Brabletz, S. et al. (2010) The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep., 11, 670-677.
21. D'Amato, N.C. et al. (2013) MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett., 341, 46-55.
22. Thiery, J.P. et al. (2009) Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-890.
23. Gibbons, D.L. et al. (2009) Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev., 23, 2140-2151.
24. Dykxhoorn, D.M. et al. (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One, 4, e7181.
25. Korpal, M. et al. (2011) Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med., 17, 1101-1108.
26. Feng, X. et al. (2014) MiR-200, a new star miRNA in human cancer. Cancer Lett., 344, 166-173.
27. Hill, L. et al. (2013) ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int. J. Cancer, 132, 745-754.
28. Howe, E.N. et al. (2012) The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J. Mammary Gland Biol. Neoplasia, 17, 65-77.
29. Griner, E.M. et al. (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer, 7, 281-294.
30. Konopatskaya, O. et al. (2010) Protein kinase Calpha: disease regulator and therapeutic target. Trends Pharmacol. Sci., 31, 8-14.
31. Kim, J. et al. (2011) Sustained inhibition of PKCa reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene, 30, 323-333.
32. Tam, W.L. et al. (2013) Protein kinase Ca is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell, 24, 347-364.
33. Tonetti, D.A. et al. (2012) PKCa and ERβ are associated with triplenegative breast cancers in African American and Caucasian patients. Int. J. Breast Cancer, 2012, 740353.
34. Wang, Z. et al. (2011) Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by microRNA-200b. Toxicol. Sci., 121, 110-122.
35. Zhao, Y. et al. (2011) Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells. Cancer Lett., 313, 54-63.
36. Wang, Z. et al. (2012) Akt activation is responsible for enhanced migratory and invasive behavior of arsenic-transformed human bronchial epithelial cells. Environ. Health Perspect., 120, 92-97.
37. Zhao, Y. et al. (2010) Perfluorooctanoic acid effects on steroid hormone and growth factor levels mediate stimulation of peripubertal mammary gland development in C57BL/6 mice. Toxicol. Sci., 115, 214-224.
38. Yang, C. et al. (2005) Rac-GAP-dependent inhibition of breast cancer cell proliferation by 2-chimerin. J. Biol. Chem., 280, 24363-24370.
39. Neve, R.M. et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10, 515-527.
40. Li, X. et al. (2013) MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene (E-pub ahead of print 16 September 2013). doi:10.1038/onc.2013.370.
41. Sugimura, R. et al. (2010) Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases. Birth Defects Res. C. Embryo Today, 90, 243-256.
42. Burridge, K. et al. (2004) Rho and Rac take center stage. Cell, 116, 167-179.
43. Katz, E. et al. (2012) Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget, 3, 608-619.
44. Wertheimer, E. et al. (2012) Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell. Signal., 24, 353-362.
45. Uhlmann, S. et al. (2010) miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene, 29, 4297-4306.
46. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
47. Howe, E.N. et al. (2011) Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res., 13, R45.
48. Sossey-Alaoui, K. et al. (2009) The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J. Biol. Chem., 284, 33019-33029.
49. Roychowdhury, D. et al. (2003) Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer. Semin. Oncol., 30(2 suppl. 3), 30-33.
50. Mochly-Rosen, D. et al. (2012) Protein kinase C, an elusive therapeutic target? Nat. Rev. Drug Discov., 11, 937-957.